Aclarion, Inc., (ACON): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACON Stock Price Chart Interactive Chart >
ACON Price/Volume Stats
| Current price | $0.70 | 52-week high | $4.05 |
| Prev. close | $0.73 | 52-week low | $0.38 |
| Day low | $0.70 | Volume | 3,608 |
| Day high | $0.77 | Avg. volume | 35,487 |
| 50-day MA | $0.73 | Dividend yield | N/A |
| 200-day MA | $0.84 | Market Cap | 5.50M |
Aclarion, Inc., (ACON) Company Bio
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Latest ACON News From Around the Web
Below are the latest news stories about ACLARION INC that investors may wish to consider to help them evaluate ACON as an investment opportunity.
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician AdvisorMarks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announce |
Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday! |
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine SymposiumNociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP. BROOMFIELD, CO , Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is lev |
Insiders who bought stock earlier this year lose -US$213k as Aclarion, Inc. (NASDAQ:ACON) drops to US$4.7mInsiders who acquired US$278k worth of Aclarion, Inc.'s ( NASDAQ:ACON ) stock at an average price of US$2.59 in the... |
ACON Price Returns
| 1-mo | -3.99% |
| 3-mo | 20.69% |
| 6-mo | -10.03% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 20.69% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...